Trevena (NASDAQ:TRVN) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN) in a research note issued to investors on Sunday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Trevena Stock Up 11.0 %

Shares of TRVN stock opened at $1.72 on Friday. Trevena has a fifty-two week low of $1.13 and a fifty-two week high of $19.23. The firm’s 50 day moving average price is $3.36 and its two-hundred day moving average price is $6.00. The stock has a market cap of $1.48 million, a price-to-earnings ratio of -0.03 and a beta of 1.08.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($9.25) by $9.02. The company had revenue of $0.33 million during the quarter. On average, equities analysts forecast that Trevena will post -32.25 EPS for the current fiscal year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.